Ultra-rapid outpatient treatment of patients with severe aortic stenosis presenting with acute valve syndrome: evaluation of a novel pathway for urgent TAVI Authors: Jonathan Vibhishanan, Kate Winn, Joao Ferreira-Martins, Harish Sharma, Ali Hosin, Katie Konstanciak, Joana Matos Dias, Joao Gurreiro De Almeida, Claudia Hundertmark, Samantha Bulman, James N Fullerton, Sam Dawkins, Russell Franks, Rajesh K Kharbanda, James D Newton, Adrian P Banning, Thomas J Cahill Published: 2026 ABSTRACT AbstractBackgroundUp to 30% of patients undergoing transcatheter aortic valve implantation (TAVI) have presented to hospital with acute decompensation of aortic stenosis (acute valve syndrome, (AVS)). Such patients conventionally undergo inpatient work-up and treatment by TAVI, associated with prolonged hospital stays, deconditioning and delayed recovery. This study aimed to evaluate the impact and feasibility of an ultra-rapid outpatient pathway for selected, stabilised AVS patients undergoing treatment by TAVI.MethodsThis single-centre cohort study with preimplementation and postimplementation comparison included consecutive AVS patients referred for TAVI over 6 months pre-pathway implementation and 12 months post-pathway implementation. Those meeting prespecified criteria were discharged home for completion of work-up and treatment by TAVI within 2 weeks. The primary efficacy endpoint was length of hospital stay. The primary safety endpoint was death or acute decompensation prior to TAVI.Results183 patients were included, of which 105 were evaluated for outpatient treatment after ultra-rapid pathway introduction. 58/105 (55.2%) met criteria for outpatient treatment, the remaining 47/105 (44.8%) were managed as inpatients. There was no significant difference in demographic or echocardiographic characteristics between management pathways. Patients treated as an outpatient had a shorter median total length of hospital stay (outpatient 12 days (IQR 7–17) vs inpatient 20 days (IQR 15–32), p<0.0001), saving an estimated 210 hospital bed-days. There was no significant difference in median time from referral to TAVI (outpatient 15 days (IQR 13–20) vs inpatient 14 days (IQR 10–18), p=0.22), nor in the incidence of the safety endpoint prior to TAVI between pathways (outpatient 6.9% vs inpatient 6.4%, HR 0.97, 95% CI 0.22 to 4.34, p=0.97), or after new pathway implementation (pre-pathway 6.7%, post-pathway 6.7%, HR 0.70, 95% CI 0.17 to 2.80, p=0.61).ConclusionsAn ultra-rapid outpatient pathway for selected AVS patients undergoing treatment by TAVI can successfully reduce total length of hospital stay. Further work is required to validate this approach.Keywords: Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis, Heart Valve Prosthesis Implantation WHAT IS ALREADY KNOWN ON THIS TOPIC A significant, growing number of transcatheter aortic valve implantation (TAVI) procedures are performed urgently in patients presenting with acute decompensation of aortic stenosis. A significant, growing number of transcatheter aortic valve implantation (TAVI) procedures are performed urgently in patients presenting with acute decompensation of aortic stenosis. Conventionally, these patients remain as inpatients from presentation until their TAVI procedure, with the prolonged inpatient stay being associated with immobility, deconditioning and delayed recovery. Conventionally, these patients remain as inpatients from presentation until their TAVI procedure, with the prolonged inpatient stay being associated with immobility, deconditioning and delayed recovery. WHAT THIS STUDY ADDS A large proportion of patients presenting with acute decompensation of aortic stenosis requiring treatment by TAVI are suitable for treatment on an ultra-rapid outpatient pathway. A large proportion of patients presenting with acute decompensation of aortic stenosis requiring treatment by TAVI are suitable for treatment on an ultra-rapid outpatient pathway. Treatment on this pathway in this real-world cohort was associated with a significantly reduced inpatient length of stay, with low rates of readmission, decompensation or death prior to treatment by TAVI. Treatment on this pathway in this real-world cohort was associated with a significantly reduced inpatient length of stay, with low rates of readmission, decompensation or death prior to treatment by TAVI. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY Adoption of similar pathways in other large-volume TAVI centres may successfully reduce the total inpatient length of stay for patients presenting with acute decompensation of aortic stenosis requiring treatment by TAVI. Adoption of similar pathways in other large-volume TAVI centres may successfully reduce the total inpatient length of stay for patients presenting with acute decompensation of aortic stenosis requiring treatment by TAVI. Introduction Aortic stenosis (AS) is a common, progressive valvular pathology with a prevalence that increases with age, affecting 1.3% of adults over 65 years of age.1 Treatment of symptomatic severe AS by transfemoral transcatheter aortic valve implantation (TAVI) has a class I indication for older patients with suitable tricuspid aortic valve anatomy across the spectrum of surgical risk.2 3 A growing number of TAVI procedures are performed urgently, after acute decompensation of AS leading to admission to hospital; in the UK, this represented 26% of all TAVIs in 2024 to 2025, with worldwide rates reported between 10% and 30%.4–6 Decompensation of AS has recently been termed ‘acute valve syndrome’ (AVS), defined as an AS presentation with acute, advanced or severe signs or symptoms, distinguished from progressive valve syndrome which comprises worsening symptoms without acuity or decompensation.7 Patients presenting with AVS conventionally remain in hospital until treatment by TAVI. This leads to a prolonged inpatient stay, due to the need for medical stabilisation, work-up including dedicated investigations such as TAVI CT, and heart valve team discussion preprocedure, with associated immobility, deconditioning and delayed recovery. Clinical outcomes after urgent TAVI are markedly inferior to elective TAVI, with a threefold higher 30-day mortality.6 Evidence-based strategies are required to streamline pathways and optimise post-TAVI outcomes for patients presenting with AVS. This study aimed to establish the feasibility of an ultra-rapid urgent outpatient TAVI pathway for selected patients presenting with AVS after a period of initial stabilisation, and to assess the safety and efficacy of this pathway compared with the standard of care. Methods Study design and overall inclusion criteria This was a prospective non-randomised cohort study conducted between May 2024 and October 2025 at a single large-volume TAVI centre in the UK. All consecutive patients presenting with AVS and referred for inpatient TAVI during this period were included in this study. Since 2020, our practice evolved to discharging a small number of selected patients with AVS for early outpatient TAVI, without strict inclusion criteria or a defined pathway. Phase 1 followed this practice, with physician choice of inpatient or outpatient work-up and treatment. In phase 2, patients were evaluated against specific, predefined clinical, echocardiographic and social criteria, and considered for discharge and treatment by TAVI within 14 days on an ultra-rapid outpatient pathway. Data was collected from patient records, and was complete unless otherwise stated. Ultra-rapid outpatient pathway inclusion and exclusion criteria Adult patients were considered for treatment with urgent TAVI on the ultra-rapid outpatient pathway if they had (1) an admission to hospital with AVS, (2) stabilised symptoms and haemodynamics on optimised medical therapy, (3) confirmed echocardiographic evidence of severe AS and (4) sufficient social support for discharge home and to attend outpatient clinic review. The exclusion criteria for the pathway were (1) presentation with cardiogenic shock, (2) refractory heart failure, (3) ongoing need for intravenous diuresis, (4) prior admission with AVS, (5) presentation with exertional syncope, (6) renal failure (either acute kidney injury (AKI) or stable chronic kidney disease stage ≥4), (7) cognitive impairment, (8) requirement for non-transfemoral access (figure 1A). (A) Summary of inclusion and exclusion criteria for the ultra-rapid outpatient pathway. (B) Pathway for patients included in phase 2 of the study. AKI, acute kidney injury; AS, aortic stenosis; CKD, chronic kidney disease; IV, intravenous; OP, outpatient; TAVI, transcatheter aortic valve implantation. Ultra-rapid outpatient pathway design Patients meeting the above criteria after remote review were discharged home from their referring centre with appropriate safety-netting advice, for outpatient clinic review at the TAVI centre, completion of remaining work-up investigations if required, heart valve team discussion, and treatment by TAVI within 14 days of discharge (figure 1B). Patients were contacted by telephone every 48–72 hours by the structural advanced nurse practitioner team to confirm clinical stability, to reinforce safety-netting advice, and to organise admission to the TAVI centre ahead of schedule if clinically necessary. Transcatheter aortic valve implantation All patients underwent gated cardiac CT angiography for procedural planning and were discussed at a heart valve team meeting. All TAVI procedures were performed by transfemoral access under local anaesthesia with conscious sedation. The choice of valve prosthesis and procedural strategy was at the implanting physician’s discretion. Endpoints and definitions The primary efficacy endpoint was total hospital length of stay. The primary safety endpoint was a composite of all-cause mortality, decompensation, or readmission due to AS while awaiting TAVI. Secondary safety endpoints were all-cause mortality in hospital and at 30 days, stroke or transient ischaemic attack, aortic valve re-intervention, procedural complications (conversion to open heart surgery, annular rupture, aortic dissection, coronary obstruction, device embolisation, perforation, life-threatening bleeding, major vascular complication, AKI, new conduction disturbances), and readmission after TAVI.8 Total length of stay was calculated from admission at the index (referring) hospital to final discharge from the TAVI centre. Patients who died prior to discharge were not included in length of stay calculations. Statistical analysis Our sample size was based on running the ultra-rapid outpatient pathway for 1 year. Data are presented as frequency (percentage), mean±SD, median (IQR), or HR (95% CI). Inter-pathway comparisons were performed using χ2 or Fisher’s exact test for categorical data, Student’s t-test for parametric continuous data and the Mann-Whitney U test for continuous non-parametric data. Log rank test and cox regression analysis were used to identify the impact of treatment pathway on the safety endpoint. HR are presented as adjusted for age and sex to reduce confounding unless otherwise specified. A two-sided p<0.05 was considered statistically significant. Statistical analyses and graph design were performed using R software V.4.5.1 (R Foundation for Statistical Computing). Flow-diagrams were generated using Canva. Results Patient pathway 183 consecutive patients admitted with AVS of AS were evaluated between May 2024 and October 2025. In phase 1, 50 patients were evaluated of which 45/50 (90%) were suitable for treatment by TAVI. Of these, 35/45 (77.8%) were treated as inpatients and 10/45 (22.2%) were discharged home prior to TAVI (online supplemental figure 1). In phase 2, 133 patients were evaluated of which 105/133 (78.9%) were suitable for treatment by TAVI (figure 2). Of these, 58/105 (55.2%) met criteria for treatment on the ultra-rapid outpatient pathway. Flow diagram showing patients included in phase 2 of the study. AS, aortic stenosis; AVS, acute valve syndrome; BAV, balloon aortic valvuloplasty; IP, inpatient; OP, outpatient; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation. Patient characteristics The mean age across the entire cohort was 80.8±8.4 years. Compared with phase 1, the phase 2 cohort had a higher proportion of female patients (39% vs 20%, p=0.038) and a higher median Rockwood clinical frailty score (4 (IQR 3–4) vs 3 (IQR 3–4), p=0.003), but demographics were otherwise similar between phases. Patients had similar echocardiographic characteristics, including mean left ventricular ejection fraction (LVEF) (phase 1: 45%±15%, phase 2: 47%±13%, p=0.321) and aortic valve mean gradient (phase 1: 45±17 mm Hg, phase 2: 48±21 mm Hg, p=0.482). Online supplemental table 1 details phase 1 baseline characteristics separated by management pathway and comparisons between phase 1 and phase 2 baseline characteristics. During phase 2, patients treated on ultra-rapid outpatient pathway had a lower mean Euroscore II compared with those treated as inpatients (4.7%±4.0% vs 5.4%±6.7%, p=0.038) but the groups were otherwise comparable in background characteristics including age, sex, body mass index and frailty scores (table 1). All echocardiographic parameters were comparable, with a similar mean LVEF (ultra-rapid outpatient 46%±12%, inpatient 49%±14%, p=0.207) and aortic valve mean gradient (ultra-rapid outpatient 44±19 mm Hg, inpatient 52±22 mm Hg, p=0.072; table 1). Table 1Baseline clinical and echocardiographic characteristics for phase 2Mean±SD or median (IQR) or n/N (%)Phase 2 inpatient (n=47)Phase 2 outpatient (n=58)P valueAge (years)80.6±10.881.2±7.60.775Female sex16/47 (34%)25/58 (43%)0.456BMI (kg/m2)26.3±6.126.2±5.00.929EuroSCORE II (%)5.4±6.74.7±4.0 0.038* STS PROM (%)6.9±5.15.2±3.10.054Hypertension26/47 (55%)35/58 (60%)0.749Diabetes mellitus15/47 (32%)18/58 (31%)1.000PVD2/47 (4%)3/58 (5%)1.000AF/flutter17/47 (36%)28/58 (48%)0.950Prior stroke/TIA6/47 (13%)10/58 (17%)0.718Chronic lung disease8/47 (17%)10/58 (17%)1.000Prior MI/PCI4/47 (9%)13/58 (22%)0.066Prior CABG4/47 (9%)4/58 (7%)1.000Prior PPM/ICD/CRT5/47 (11%)5/58 (9%)0.987Current/ex-smoker14/39 (36%)25/47 (53%)0.166Rockwood score median4 (3–4)4 (3–4)0.255Katz Index median6 (6–6)6 (6–6)0.835eGFR (mL/min/1.73 m2)62±2058±170.301NYHA III/IV34/47 (72%)39/58 (67%)0.725LVEF (%)49±1446±120.207AV maximum velocity (m/s)4.4±1.04.2±0.90.244AV peak gradient (mmHg)83±3371±280.067AV mean gradient (mmHg)52±2244±190.072AV area (cm2)0.71±0.320.77±0.560.500DVI0.21±0.070.21±0.080.956≥moderate AV regurgitation13/45 (29%)16/56 (29%)1.000≥moderate MV regurgitation16/46 (35%)22/56 (39%)0.793≥moderate TV regurgitation6/46 (13%)16/56 (29%)0.098All percentages have been rounded to the nearest whole number and thus may not always add to 100%.*p<0.05. P values that reach statistical significance have been displayed in bold.AF, atrial fibrillation; AV, aortic valve; BMI, body mass index; CABG, coronary artery bypass graft; CRT, cardiac resynchronisation therapy; DVI, dimensionless valve index; eGFR, estimated glomerular filtration rate; EuroSCORE, European System for Cardiac Operative Risk Evaluation; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MV, mitral valve; NYHA, New York Heart Association class; PCI, percutaneous coronary intervention; PPM, permanent pacemaker; PVD, peripheral vascular disease; STS PROM, The Society of Thoracic Surgeons Predicted Risk of Mortality; TIA, transient ischaemic attack; TV, tricuspid valve. Baseline clinical and echocardiographic characteristics for phase 2 All percentages have been rounded to the nearest whole number and thus may not always add to 100%. *p<0.05. P values that reach statistical significance have been displayed in bold. AF, atrial fibrillation; AV, aortic valve; BMI, body mass index; CABG, coronary artery bypass graft; CRT, cardiac resynchronisation therapy; DVI, dimensionless valve index; eGFR, estimated glomerular filtration rate; EuroSCORE, European System for Cardiac Operative Risk Evaluation; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MV, mitral valve; NYHA, New York Heart Association class; PCI, percutaneous coronary intervention; PPM, permanent pacemaker; PVD, peripheral vascular disease; STS PROM, The Society of Thoracic Surgeons Predicted Risk of Mortality; TIA, transient ischaemic attack; TV, tricuspid valve. Clinical presentation Table 2 details clinical presentations in phase 2. The dominant presentation was pulmonary oedema; this was more common on the ultra-rapid outpatient pathway than the inpatient pathway (47/58 (81%) vs 27/47 (57%), p=0.015). Exertional syncope was an exclusion criterion for the ultra-rapid outpatient pathway, conferring a significant difference in the incidence of all syncope between the groups (ultra-rapid 3/38 (5%) vs inpatient 16/47 (34%), p<0.001). Table 2Clinical presentation during phase 2n/N (%)Phase 2 inpatient (n=47)Phase 2 outpatient (n=58)P valueChest pain15/47 (32%)21/58 (36%)0.780Presyncope10/47 (21%)10/58 (17%)0.784Syncope16/47 (34%)3/58 (5%) <0.001*** Pulmonary oedema27/47 (57%)47/58 (81%) 0.015* Rapid symptom progression8/47 (17%)7/58 (12%)0.659All percentages have been rounded to the nearest whole number.Patients may have had several components to their presentation, meaning the total exceeds 100%.*p<0.05, ***p<0.001. P values that reach statistical significance have been displayed in bold. Clinical presentation during phase 2 All percentages have been rounded to the nearest whole number. Patients may have had several components to their presentation, meaning the total exceeds 100%. *p<0.05, ***p<0.001. P values that reach statistical significance have been displayed in bold. Pathway outcomes: efficacy There was no significant difference between the median time from referral to TAVI between phase 1 and phase 2 (table 3). For patients treated as an outpatient, the introduction of the ultra-rapid pathway substantially reduced the time from referral to TAVI (59 days (IQR 42–64) vs 15 days (IQR 13–20), p=0.002; table 3). There was a small reciprocal increase in the time from referral to TAVI for patients treated as inpatients between phase 1 and phase 2 (12 days (IQR 8–14) vs 14 days (IQR 10–18), p=0.02). Table 3Pathway outcomesMedian (IQR) (days) or n/N (%)Phase 1(n=45)Phase 2(n=105)P valuePhase 2 inpatient(n=47)Phase 2 outpatient(n=58)P valueTime from referral to TAVI13 (8–22)14 (12–20)0.11714 (10–18)15 (13–20)0.216Inpatient group12 (8–14)14 (10–18) 0.020* Outpatient group59 (42–64)15 (13–20) 0.002** Pre-TAVI LOS15 (9–22)13 (8–20)0.14317 (12–27)10 (5–15) <0.0001*** Post-TAVI LOS1 (1–4)1 (1–3)0.7592 (1–3)1 (1–2) 0.019* Total hospital LOS18 (12–22)16 (11–24)0.43720 (15–32)12 (7–17) <0.0001*** Decompensation or readmission prior to TAVI1/45 (2%)2/105 (2%)1.000N/A2/58 (3%)N/ADeath prior to TAVI2/45 (4%)5/105 (5%)1.0003/47 (6%)2/58 (3%)0.655Decompensation or readmission or death prior to TAVI3/45 (7%)7/105 (7%)1.0003/47 (6%)4/58 (7%)1.000All percentages have been rounded to the nearest whole number and thus may not always add to 100%.Please note that the patient who underwent a BAV has not had their postprocedural LOS analysed with the remainder of the cohort.*p<0.05, **p<0.01, ***p<0.001. P values that reach statistical significance have been displayed in bold. BAV, balloon aortic valvuloplasty; LOS, length of stay; N/A, not available; TAVI, transcatheter aortic valve implantation. Pathway outcomes All percentages have been rounded to the nearest whole number and thus may not always add to 100%. Please note that the patient who underwent a BAV has not had their postprocedural LOS analysed with the remainder of the cohort. *p<0.05, **p<0.01, ***p<0.001. P values that reach statistical significance have been displayed in bold. BAV, balloon aortic valvuloplasty; LOS, length of stay; N/A, not available; TAVI, transcatheter aortic valve implantation. During phase 2, there was no significant difference in the median time from referral to TAVI between the parallel inpatient and ultra-rapid outpatient pathways (14 days (IQR 10–18) vs 15 days (IQR 13–20), p=0.216; table 3). Compared with those treated as inpatients, patients treated on the ultra-rapid outpatient pathway had a significantly shorter median pre-TAVI length of stay (10 days (IQR 5–15) vs 17 days (IQR 12–27), p<0.0001), total hospital length of stay (12 days (IQR 7–17) vs 20 days (IQR 15–32), p<0.0001) (figure 3) and post-TAVI length of stay (1 day (IQR 1–2) vs 2 days (IQR 1–3), p=0.019; table 3). In phase 2, this saved an estimated 210 hospital bed-days. Box plots comparing length of stay between conventional inpatient pathway and ultra-rapid outpatient pathway: (A) Pre-TAVI inpatient length of stay. (B) Total length of stay. ***p<0.001. TAVI, transcatheter aortic valve implantation. More patients on the ultra-rapid outpatient pathway were discharged directly home from the TAVI centre (outpatient 53/53 (100%), inpatient 39/43 (91%), p=0.037). Three patients (3/43, 7%) treated as inpatients were repatriated to their referring hospital, and one (1/43, 2%) was discharged to a rehabilitation unit. Pathway outcomes: safety In phase 1, two patients (2/45, 4%) died in hospital while awaiting inpatient TAVI. The first decompensated with multiorgan failure on a background of end-stage renal failure. The second suffered an unheralded cardiac arrest on the ward. In phase 2, three patients (3/47, 6%) on the inpatient pathway died prior to TAVI. The first had a massive upper gastrointestinal bleed, with unsuccessful resuscitation. The second had presented after a resuscitated cardiac arrest and then developed Staphylococcus aureus bacteraemia, ultimately dying from this. The third died at their referring hospital, with no further detail available. Two patients (2/58, 3%) died on the ultra-rapid outpatient pathway prior to TAVI, one at home and one after readmission. The patient at home reported worsening breathlessness and readmission had been advised, but the patient had declined and was found deceased the following day. The readmitted patient reported shortness of breath, and had developed sepsis secondary to a respiratory infection, dying from this. There was no significant difference in the incidence of death prior to TAVI between phase 1 and phase 2 (4.4% vs 4.8%, HR 0.69, 95% CI 0.13 to 3.7, p=0.66). There was no significant difference in these outcomes over time (figure 4). Kaplan-Meier plots comparing conventional inpatient pathway and ultra-rapid outpatient pathway from referral to urgent TAVI, for: (A) survival. (B) Freedom from the safety composite outcome of death, decompensation or readmission prior to TAVI. TAVI, transcatheter aortic valve implantation. In phase 1, one patient (1/10, 10%) on the (ad hoc) outpatient pathway was readmitted prior to their planned date having had a non-ST segment elevated myocardial infarction. In phase 2, two patients (2/58, 3%) on the ultra-rapid outpatient pathway were readmitted ahead of their scheduled TAVI: one was admitted from clinic after falling to undergo inpatient TAVI, the other is detailed above. Another patient was admitted as scheduled, but had developed a respiratory infection, and was instead treated by balloon aortic valvuloplasty. There was no significant difference in the incidence of readmission prior to TAVI between phase 1 and phase 2 (2.2% vs 1.9%, HR 0.72, 95% CI 0.06 to 8.5, p=0.79). There was no significant difference in the incidence of pre-TAVI safety endpoint composite of death, readmission or decompensation between ultra-rapid outpatient and inpatient management (outpatient 6.9% vs inpatient 6.4%, HR 0.97, 95% CI 0.22 to 4.34, p=0.97; figure 4), or after the introduction of the ultra-rapid outpatient pathway (phase 1: 6.7%, phase 2: 6.7%, HR 0.70, 95% CI 0.17 to 2.8, p=0.61). There was no significant difference in these outcomes over time (figure 4). Clinical outcomes post-TAVI 43/45 (96%) patients in phase 1 and 99/105 (94%) patients in phase 2 underwent treatment by TAVI. In phase 2, this comprised 44/47 (94%) patients on the inpatient pathway and 55/58 (95%) patients on the ultra-rapid outpatient pathway, with one in the latter group undergoing inpatient TAVI as above. Online supplemental table 2 details procedural outcomes. In phase 1, two patients (2/43, 4%) died after TAVI but before discharge: the first sustained a coronary perforation during planned concomitant complex percutaneous coronary intervention performed directly after TAVI, and the second died after developing an infective exacerbation of interstitial lung disease which progressed to multiorgan failure. In phase 2, one patient on the inpatient pathway (1/44, 2%) and two patients on the ultra-rapid outpatient pathway (2/55, 4%) died after TAVI but before discharge. The patient on the inpatient pathway arrested with a pericardial tamponade, with ongoing intermittent arrests after drainage. Both on the ultra-rapid outpatient pathway died from intraprocedural complications, with the first sustaining an iatrogenic Gerbode defect during postdilatation with a persistent paravalvular leak. The second sustained an annular injury with pericardial tamponade, who died despite surgical intervention. There was no significant difference in the incidence of post-TAVI mortality between phase 1 and phase 2 (2/43 (4%) vs 3/99 (3%), p=0.639) (table 4). Between TAVI and discharge, three patients (3/99, 3%) in phase 2 suffered from stroke or transient ischaemic attack, one patient (1/99, 1%) in phase 2 required aortic valve reintervention, one patient in phase 1 (1/43, 2%) and four patients in phase 2 (4/99, 4%) suffered major bleeding, and one patient in phase 1 (1/43, 2%) and five patients in phase 2 (5/99, 5%) suffered a major vascular complication. Three patients in phase 1 (3/43, 7%) and four patients in phase 2 (4/99, 4%) suffered from AKI. Three patients in phase 1 (3/43, 7%) and 13 patients in phase 2 (13/99, 13%) required a new permanent pacemaker (PPM) post-TAVI (table 4). There were no significant differences between phase 1 and phase 2, within the limitations of this study (table 4). Table 4Clinical outcomes after TAVI (up to discharge)n/N (%)Phase 1(n=43)Phase 2(n=99)P valuePhase 2 inpatient(n=44)Phase 2 outpatient(n=55)P valueAll-cause mortality2/43 (4%)3/99 (3%)0.6391/44 (2%)2/55 (4%)1.000Stroke/TIA0/43 (0%)3/99 (3%)0.5543/44 (7%)0/55 (0%)0.087Aortic valve reintervention0/43 (0%)1/99 (1%)1.0001/44 (2%)0/55 (0%)1.000Major or life-threatening bleeding1/43 (2%)4/99 (4%)1.0002/44 (5%)2/55 (4%)1.000Major vascular complication1/43 (2%)5/99 (5%)0.6683/44 (7%)2/55 (4%)0.653New PPM post-TAVI3/43 (7%)13/99 (13%)0.3923/44 (7%)10/55 (18%)0.136Acute kidney injury3/43 (7%)4/99 (4%)0.4333/44 (7%)1/55 (2%)0.320All percentages have been rounded to the nearest whole number and thus may not always add to 100%.PPM, permanent pacemaker; TAVI, transcatheter aortic valve implantation; TIA, transient ischaemic attack. Clinical outcomes after TAVI (up to discharge) All percentages have been rounded to the nearest whole number and thus may not always add to 100%. PPM, permanent pacemaker; TAVI, transcatheter aortic valve implantation; TIA, transient ischaemic attack. At 30 days post-TAVI, one further patient died in each of phase 1 and phase 2 (online supplemental table 3). The patient in phase 1 died after repatriation to their referring hospital, with no further detail available. The patient in phase 2 died 16 days after discharge home, with no further detail available. There was no significant difference between phases in the incidence of death between referral and 30 days postprocedure after the introduction of the ultra-rapid outpatient pathway (phase 1: 8.9%, phase 2: 8.6%, HR 0.84, 95% CI 0.25 to 2.8, p=0.77), nor was there any significant difference in the overall incidence of the secondary safety endpoint (phase 1: 20.0%, phase 2: 27.6%, HR 1.49, 95% CI 0.71 to 3.2, p=0.29 which could not be adjusted for age and sex), within the limitations of this study. Discussion This is the first study evaluating the feasibility of an outpatient TAVI treatment pathway for selected AS patients presenting with AVS. The key findings are as follows: (1) over half of patients presenting with AVS suitable for treatment by TAVI in a real-world cohort can be treated on an ultra-rapid outpatient pathway; (2) introduction of an ultra-rapid outpatient pathway is associated with a substantial reduction in the total length of hospital stay for this group, with no significant difference in time from referral to treatment by TAVI; (3) patients on an ultra-rapid outpatient pathway for AVS have low rates of unplanned readmission, decompensation or death prior to TAVI, equivalent to the rate observed for those in hospital and (4) clinical outcomes after TAVI for patients treated on an ultra-rapid outpatient pathway are similar to those treated as an inpatient within the limitations of the study, with a higher rate of discharge home. AVS in AS Acute decompensation of AS has been recognised as the requirement for hospitalisation due to an acute deterioration of symptoms associated with AS, often with pulmonary congestion or signs of heart failure.9 10 The recent description of AVS by Généreux et al defines this as an AS presentation due to acute, advanced or severe signs or symptoms, encompassing cardiac arrest or resuscitated sudden death, cardiogenic shock, acute heart failure with pulmonary oedema, New York Heart Association (NYHA) class III–IV, syncope, angina with Canadian Cardiovascular Society grade III-IV, new-onset atrial fibrillation or ventricular fibrillation, increase in heart failure biomarkers ≥3 times above the age-adjusted upper limit of normal, or a new decrease in LVEF of >10%.7 This new definition distinguishes AVS from progressive valve syndrome, where patients have mild (ie, NYHA class II) symptoms and/or a rise in biomarkers below the thresholds above.7 11 Urgent TAVI Presentation with AVS represents an advanced stage of AS requiring urgent treatment.7 Conventionally, patients remain in hospital until treatment, but the benefits of this approach are not established, while many cardiovascular conditions are increasingly managed in ambulatory care.12 13 In patients treated by TAVI, urgent treatment is associated with a 30-day and 1-year mortality rate up to three times higher compared with elective treatment.5 14 15 There are likely multiple causes for this, including a comorbid patient group with advanced disease and cardiac damage, possibly with further deconditioning associated with a prolonged inpatient stay. In the UK, the median length of stay for urgent TAVI is 14 days compared with 2 days for elective patients.6 Prolonged hospitalisation for an elderly cohort has been linked to increased readmission, hospital-acquired infection, frailty and loss of social support.16–19 Urgent TAVI is also associated with a greater incidence of complications, including AKI and vascular complications.5 20 21 A recent consensus document on the proactive management of AS has emphasised the importance of treating symptomatic patients with greater urgency.22 Prior investigations into TAVI pathways Reducing TAVI length of stay and the conferred benefits have been demonstrated in the elective setting by several prior studies.23–26 However, only the ASessment and TReatment In Decompensated AS (ASTRID-AS) study has examined a streamlined process for TAVI in the inpatient setting, which reduced the median length of stay by 11 days (from 24 to 13 days) for patients awaiting inpatient TAVI by expediting diagnosis, referral, investigation, and treatment while keeping patients admitted from referral to TAVI.27 Current study The current study evaluated a structured, ultra-rapid outpatient pathway for selected patients with AVS who were suitable for treatment by TAVI. This pathway used predefined criteria to select suitable patients for discharge and treatment by TAVI, excluding those felt to be at highest risk of further instability or decompensation, or those with inadequate social support. The pathway reduced the median pre-TAVI and the total hospital length of stay by 7 and 8 days, respectively. It also reduced the median post-TAVI length of stay by 1 day, possibly reflecting a lower level of deconditioning or preserved home set-up associated with a shorter inpatient spell.28 29 Importantly, it did not increase the overall time from referral to TAVI procedure, with no significant differences in time from referral to TAVI between those treated on the outpatient pathway and those treated as inpatients, or between the pre-pathway implementation and post-pathway implementation cohorts. Additionally, across 1 year, an estimated 210 hospital bed-days were saved at a high-volume TAVI-centre. Notably, those discharged on the ultra-rapid outpatient pathway were comparably elderly and frail to those treated on the inpatient pathway, with the median frailty increasing after pathway implementation. This represents a cohort of patients in which reducing the inpatient length of stay has been associated with reduced frailty, risk of re-admission, hospital acquired infection and loss of social support.16–19 Introduction of the pathway increased the proportion of female patients treated by urgent TAVI, although this remained under half. This is in line with the current literature, in which a lower proportion of all TAVI procedures performed are done so for female patients (42% in the UK from 2024 to 2025), despite these patients representing over half of the general population over 75, and having similar rates of valvular heart disease.1 6 Of TAVI procedures performed, a similar proportion are required urgently in female and male patients.6 Notably, a greater proportion (non-significant) of those treated on the ultra-rapid outpatient pathway were female compared with those not suitable for the ultra-rapid outpatient pathway (43% vs 34%, p=0.456). Further work is required to validate this effect. Patients were closely monitored throughout, with a telephone review by an advanced nurse practitioner every 48–72 hours. Within the limitations of this non-randomised, small-cohort feasibility study we observed similar rates of mortality and decompensation, and similar procedural outcomes to discharge and 30 days, compared with patients remaining as an inpatient. Implications An ultra-rapid outpatient pathway for selected patients with AVS can potentially significantly reduce the length of hospital stay while preserving the total time from referral to TAVI, with no excess of adverse outcomes observed during this study. There are potential benefits to patients in terms of preserving mobility, independence and return to the home environment. It also increases the number of available inpatient beds, allowing for more patients requiring hospitalisation to be treated in the context of hospitals increasingly functioning at or above capacity. Further work is required to determine the financial impact of the pathway. Limitations This was a proof-of-concept single centre cohort study which confers inherent limitations. The study was not randomised and was not powered to determine rates of individual complications and mortality, which require larger studies. The selection criteria for outpatient or inpatient management conferred inherent selection bias, limiting comparisons of safety outcomes and procedural complications between groups. The ultra-rapid outpatient pathway necessitates a dedicated team with time assigned to telephone-reviewing patients once discharged, which may reduce replicability. It also mandates treatment within 14 days of discharge, which requires ring-fenced beds and procedure slots. Conclusions Introduction of an ultra-rapid outpatient pathway for carefully selected patients with severe AS presenting with AVS was associated with a reduction in preprocedural and total hospital length of stay without significantly increasing the time from referral to TAVI, with no excess of adverse outcomes after pathway implementation. Further work is required to validate the safety and efficacy of this approach more broadly, and to determine financial and resource-provision implications of this pathway. Supplementary material Footnotes Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Ethics approval: The ultra-rapid outpatient pathway was developed and evaluated as a clinical service evaluation with approval and oversight of the Oxford University Hospitals clinical governance system. Data availability free text: Individual patient data are not available for confidentiality reasons. All relevant data to the study are included in either the article or the supplementary information. Data availability statement Data are available on reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information. References Associated Data Supplementary Materials Data Availability Statement Data are available on reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information.